Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma
The management of persistent coronavirus disease 2019 (COVID-19) in patients with hematological malignancies who are immunocompromised because of underlying disease or iatrogenic immunosuppression remains clinically challenging. Herein, we report an 84-year-old man with stage 3 diffuse large B-cell...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-04-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1554100/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850171447143563264 |
|---|---|
| author | Masaki Suzuki Isao Fujioka Takamitsu Matsushima |
| author_facet | Masaki Suzuki Isao Fujioka Takamitsu Matsushima |
| author_sort | Masaki Suzuki |
| collection | DOAJ |
| description | The management of persistent coronavirus disease 2019 (COVID-19) in patients with hematological malignancies who are immunocompromised because of underlying disease or iatrogenic immunosuppression remains clinically challenging. Herein, we report an 84-year-old man with stage 3 diffuse large B-cell lymphoma treated with rituximab and epcoritamab who subsequently developed persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite having received seven doses of COVID-19 mRNA vaccine and remdesivir. The patient was treated with a combination of remdesivir, sotrovimab, and nirmatrelvir/ritonavir, and recovered clinically. SARS-CoV-2 polymerase chain reaction and antigen tests eventually turned negative, and he was discharged after 28 days of hospitalization. This case highlights the challenges associated with managing persistent SARS-CoV-2 infection in immunocompromised patients with hematological malignancies. Combined treatment with antivirals and monoclonal antibodies may be an effective strategy. |
| format | Article |
| id | doaj-art-a23c62fda39b49cdba24867238931bc4 |
| institution | OA Journals |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-a23c62fda39b49cdba24867238931bc42025-08-20T02:20:16ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-04-011210.3389/fmed.2025.15541001554100Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphomaMasaki Suzuki0Isao Fujioka1Takamitsu Matsushima2Department of Respirology, Kashiwa Kousei General Hospital, Kashiwa, JapanDepartment of Hematology, Kashiwa Kousei General Hospital, Kashiwa, JapanDepartment of Hematology, Kashiwa Kousei General Hospital, Kashiwa, JapanThe management of persistent coronavirus disease 2019 (COVID-19) in patients with hematological malignancies who are immunocompromised because of underlying disease or iatrogenic immunosuppression remains clinically challenging. Herein, we report an 84-year-old man with stage 3 diffuse large B-cell lymphoma treated with rituximab and epcoritamab who subsequently developed persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, despite having received seven doses of COVID-19 mRNA vaccine and remdesivir. The patient was treated with a combination of remdesivir, sotrovimab, and nirmatrelvir/ritonavir, and recovered clinically. SARS-CoV-2 polymerase chain reaction and antigen tests eventually turned negative, and he was discharged after 28 days of hospitalization. This case highlights the challenges associated with managing persistent SARS-CoV-2 infection in immunocompromised patients with hematological malignancies. Combined treatment with antivirals and monoclonal antibodies may be an effective strategy.https://www.frontiersin.org/articles/10.3389/fmed.2025.1554100/fullpersistent COVID-19diffuse large B-cell lymphomarituximabepcoritamabSARS-CoV-2 |
| spellingShingle | Masaki Suzuki Isao Fujioka Takamitsu Matsushima Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma Frontiers in Medicine persistent COVID-19 diffuse large B-cell lymphoma rituximab epcoritamab SARS-CoV-2 |
| title | Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma |
| title_full | Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma |
| title_fullStr | Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma |
| title_full_unstemmed | Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma |
| title_short | Case Report: Persistent COVID-19 in a fully vaccinated Japanese man being treated with rituximab and epcoritamab for diffuse large B-cell lymphoma |
| title_sort | case report persistent covid 19 in a fully vaccinated japanese man being treated with rituximab and epcoritamab for diffuse large b cell lymphoma |
| topic | persistent COVID-19 diffuse large B-cell lymphoma rituximab epcoritamab SARS-CoV-2 |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1554100/full |
| work_keys_str_mv | AT masakisuzuki casereportpersistentcovid19inafullyvaccinatedjapanesemanbeingtreatedwithrituximabandepcoritamabfordiffuselargebcelllymphoma AT isaofujioka casereportpersistentcovid19inafullyvaccinatedjapanesemanbeingtreatedwithrituximabandepcoritamabfordiffuselargebcelllymphoma AT takamitsumatsushima casereportpersistentcovid19inafullyvaccinatedjapanesemanbeingtreatedwithrituximabandepcoritamabfordiffuselargebcelllymphoma |